| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; 1:500; loading ...; fig 4a
| Tan S, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, et al. A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability. Cell. 2017;169:1105-1118.e15 pubmed publisher |
- immunocytochemistry; human; 1:200; fig 3
| Zhang H, Liu H, Chen Y, Yang X, Wang P, Liu T, et al. A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun. 2016;7:10201 pubmed publisher |
- immunocytochemistry; mouse; 1:200; fig 3B
| Uringa E, Baldeyron C, Odijk H, Wassenaar E, van Cappellen W, Maas A, et al. A mRad51-GFP antimorphic allele affects homologous recombination and DNA damage sensitivity. DNA Repair (Amst). 2015;25:27-40 pubmed publisher |
| Perl A, O Connor C, Fa P, Mayca Pozo F, Zhang J, Zhang Y, et al. Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). J Biol Chem. 2019;294:17043-17059 pubmed publisher |
| Heijink A, Everts M, Honeywell M, Richards R, Kok Y, de Vries E, et al. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep. 2019;28:2345-2357.e5 pubmed publisher |
| Heijink A, Talens F, Jae L, van Gijn S, Fehrmann R, Brummelkamp T, et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat Commun. 2019;10:100 pubmed publisher |
| van Gijn S, Wierenga E, van den Tempel N, Kok Y, Heijink A, Spierings D, et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene. 2019;38:852-867 pubmed publisher |
| Mansour W, Tennstedt P, Volquardsen J, Oing C, Kluth M, Hube Magg C, et al. Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Sci Rep. 2018;8:3947 pubmed publisher |
| Browning C, Wise J. Prolonged exposure to particulate chromate inhibits RAD51 nuclear import mediator proteins. Toxicol Appl Pharmacol. 2017;331:101-107 pubmed publisher |
| Jiang Y, Verbiest T, Devery A, Bokobza S, Weber A, Leszczynska K, et al. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality. Int J Radiat Oncol Biol Phys. 2016;95:772-81 pubmed publisher |
| Zhu J, Chen H, Guo X, Qiu X, Hu C, Chamberlin A, et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. Eur J Med Chem. 2015;96:196-208 pubmed publisher |
| Waddell N, Pajic M, Patch A, Chang D, Kassahn K, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501 pubmed publisher |
| White M, Kaminski R, Khalili K, Wollebo H. Rad51 activates polyomavirus JC early transcription. PLoS ONE. 2014;9:e110122 pubmed publisher |
| Pefani D, Latusek R, Pires I, Grawenda A, Yee K, Hamilton G, et al. RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. Nat Cell Biol. 2014;16:962-71, 1-8 pubmed publisher |
| Karnak D, Engelke C, Parsels L, Kausar T, Wei D, Robertson J, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res. 2014;20:5085-96 pubmed publisher |
| Naipal K, Verkaik N, Ameziane N, van Deurzen C, Ter Brugge P, Meijers M, et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20:4816-26 pubmed publisher |
| Kaminski R, Wollebo H, Datta P, White M, Amini S, Khalili K. Interplay of Rad51 with NF-?B pathway stimulates expression of HIV-1. PLoS ONE. 2014;9:e98304 pubmed publisher |
| Pfäffle H, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013;73:6254-63 pubmed publisher |
| Engelke C, Parsels L, Qian Y, Zhang Q, Karnak D, Robertson J, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res. 2013;19:4412-21 pubmed publisher |
| Wei D, Parsels L, Karnak D, Davis M, Parsels J, Marsh A, et al. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res. 2013;19:4422-32 pubmed publisher |
| Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013;5:353-65 pubmed publisher |
| Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012;11:3837-50 pubmed publisher |
| Borst G, McLaughlin M, Kyula J, Neijenhuis S, Khan A, Good J, et al. Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys. 2013;85:1110-8 pubmed publisher |
| Sharma S, Hicks J, Chute C, Brennan J, Ahn J, Glover T, et al. REV1 and polymerase ? facilitate homologous recombination repair. Nucleic Acids Res. 2012;40:682-91 pubmed publisher |
| Lee M, Daniels M, Garnett M, Venkitaraman A. A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor. Oncogene. 2011;30:3360-9 pubmed publisher |
| Klammer H, KADHIM M, Iliakis G. Evidence of an adaptive response targeting DNA nonhomologous end joining and its transmission to bystander cells. Cancer Res. 2010;70:8498-506 pubmed publisher |
| Ammazzalorso F, Pirzio L, Bignami M, Franchitto A, Pichierri P. ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery. EMBO J. 2010;29:3156-69 pubmed publisher |
| Graeser M, McCarthy A, Lord C, Savage K, Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16:6159-68 pubmed publisher |
| Bowen C, Gelmann E. NKX3.1 activates cellular response to DNA damage. Cancer Res. 2010;70:3089-97 pubmed publisher |
| Suzuki K, Yamauchi M, Oka Y, Suzuki M, Yamashita S. A novel and simple micro-irradiation technique for creating localized DNA double-strand breaks. Nucleic Acids Res. 2010;38:e129 pubmed publisher |
| Dungey F, Caldecott K, Chalmers A. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther. 2009;8:2243-54 pubmed publisher |
| Carlessi L, De Filippis L, Lecis D, Vescovi A, Delia D. DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression. Cell Death Differ. 2009;16:795-806 pubmed publisher |
| Warren M, Lord C, Masabanda J, Griffin D, Ashworth A. Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum Mol Genet. 2003;12:2645-56 pubmed |
| Kao G, McKenna W, Guenther M, Muschel R, Lazar M, Yen T. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol. 2003;160:1017-27 pubmed |
| Masson J, Davies A, Hajibagheri N, Van Dyck E, Benson F, Stasiak A, et al. The meiosis-specific recombinase hDmc1 forms ring structures and interacts with hRad51. EMBO J. 1999;18:6552-60 pubmed |
